Allogeneic Stem Cell Transplantation Market Size is valued at USD 3.66 Bn in 2022 and is predicted to reach USD 6.75 Bn by the year 2031 at a 7.21% CAGR during the forecast period for 2023-2031.
Allogeneic stem cell transplantation, also known as allogeneic hematopoietic stem cell transplantation (HSCT), refers to transferring the significant stem cells from a healthy donor to a desired patient. The donor can either be a biological relative, typically a sibling, or an unrelated individual whose tissue type is compatible with the recipient's. HLA matching can prevent graft rejection, graft-versus-host disease (GvHD), and other complications. Stem cells are exist in both the bone marrow and the blood. Hematopoietic stem cells are nascent or undeveloped blood cells within the bone marrow. Blood cells undergo maturation in the bone marrow, but only a minuscule portion of them enter the bloodstream. The cells that enter the bloodstream are referred to as peripheral blood stem cells. Moreover, the integration of allogeneic stem cells with biomaterials to generate bioengineered tissues and organs presents innovative possibilities for addressing severe diseases and injuries. The following are the latest trends in the allogeneic stem cell industry that are driving its growth.
In Addition, the market growth is impaded by the strict regulatory criteria for the safety and health of allogeneic stem cell transplantation and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high humidity allogeneic stem cell transplantation, although regulatory rules are changing to facilitate the commercialization of cell therapies, rigorous evaluation is still required because of the lack of clarity regarding their long-term safety and effectiveness. Manufacturers must adhere to stringent restrictions from procuring stem cells via good tissue practices, cGMP standards, quality checks, and required preclinical research. To halt the spread of COVID-19, many nations have instituted nationwide lockdowns. Companies in the healthcare industry across the globe faced similar challenges when trying to keep their supply chains running smoothly. Since the frequency of new instances of COVID-19 decreased, limitations on patients visiting hospitals to receive treatment were relaxed.
Competitive Landscape
Some Major Key Players In The Allogeneic Stem Cell Transplantation Market:
- Celgene Corporation
- Mesoblast Ltd.
- Pluristem Therapeutics Inc.
- MEDIPOST Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Astellas Pharma Inc.
- Cellular Biomedicine Group, Inc.
- Biosolution Co., Ltd.
- StemCell Technologies Inc.
- Caladrius Biosciences, Inc.
- TiGenix N.V.
- ViaCord
- Vericel Corporation
- Regen Biopharma Inc.
- Gamida Cell Ltd.
- Histogenics Corporation
- BrainStorm Cell Therapeutics Inc.
- Lineage Cell Therapeutics, Inc.
- Bluebird Bio
- Sanofi
- Talaris Therapeutics.
- Others
Market Segmentation:
The allogeneic stem cell transplantation market is segmented based on source, application, end user and cell type. According to source segment, the market is segmented into bone marrow, peripheral blood, umbilical cord blood, adipose tissue, dental pulp, and others. The application segment is segmented into cancer, autoimmune diseases, blood disorders, cardiac disorders, neurological disorders, diabetes, and others. By end user, the market is segmented into hospitals, research institutes, speciality clinics, and others. By cell type, the market is segmented into allogeneic MSCs, allogeneic HSCs, and others.
Based On The Source, The Bone Marrow Segment Is A Major Contributor To The Allogeneic Stem Cell Transplantation Market.
The bone marrow allogeneic stem cell transplantation market is expected to lead with a major global market share in 2022. Bone marrow stem cell transplantation has shown promise as a potential cure for some haematological diseases, especially when standard treatments have failed or the disease has returned. For individuals who are candidates, this treatment is crucial since it can prolong life for years without relapse.
The Hospital Segment Is Witnessing Growth At A Rapid Rate.
The hospital industry makes up the bulk of allogeneic stem cell transplantation because, in modern hospitals, patients have access to state-of-the-art medical technology, including bone marrow transplantation units. These resources allow hospitals to provide comprehensive pre-and post-transplant care for HSCT recipients, especially in countries like the US, Germany, the UK, China, and India.
In The Region, The North American Allogeneic Stem Cell Transplantation Market Holds A Significant Revenue Share.
The North American allogeneic stem cell transplantation market is expected to record the maximum market share in revenue in the near future. It can be attributed to the high acceptance of stem cell therapies, improved healthcare infrastructure, and increasing R&D investments fueling the market's expansion. In addition, Asia Pacific is estimated to grow rapidly in the global allogeneic stem cell transplantation market because of the large population and increasing demand for high-quality healthcare in the region, as well as the growing number of people who are becoming more health-conscious and in need of cutting-edge medical technology for skin care.
Recent Developments:
- In September 2023, Mesoblast collaborated with the Blood & Marrow Transplant Clinical Trials Network (BMT CTN) to conduct a clinical trial examining the effectiveness of its drug, Ryoncil (remestemcel-L), in treating steroid-refractory acute graft versus host disease (SR-aGvHD). BMT CTN will undertake the trial to assess the efficacy of Ryoncil in patients aged 12 and above who have shown inadequate response to prior treatments such as corticosteroids and a second-line drug like ruxolitinib.
- In Jan 2020, Astellas and Adaptimmune formed a partnership to collaborate on the development and marketing of stem-cell derived allogeneic CAR-T and TCR T-cell treatments. The cooperation utilized Adaptimmune's ability in identifying and confirming targets to create T-cell Receptors (TCRs), chimeric antigen receptors (CARs), and HLA-independent TCRs that could recognize surface epitopes regardless of the HLA profile of the tumor cell.
Allogeneic Stem Cell Transplantation Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 3.66 Bn |
|
Revenue Forecast In 2031 |
USD 6.75 Bn |
|
Growth Rate CAGR |
CAGR of 7.21% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Source, Application, Cell Type, End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Celgene Corporation, Mesoblast Ltd., Pluristem Therapeutics Inc., MEDIPOST Co., Ltd., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Cellular Biomedicine Group, Inc., Biosolution Co., Ltd., StemCell Technologies Inc., Caladrius Biosciences, Inc., TiGenix N.V., ViaCord, Vericel Corporation, Regen Biopharma Inc., Gamida Cell Ltd., Histogenics Corporation, BrainStorm Cell Therapeutics Inc., Lineage Cell Therapeutics, Inc., Bluebird Bio, Sanofi, Talaris Therapeutics and Others
|
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
